Pharmacyte Biotech Inc (PMCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 04/30
| 07-2024 | 04-2024 | 01-2024 | 10-2023 | 07-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 23,421 | 334 | -1,013 | -393 | -3,183 |
| Accounts payable and accrued liabilities | 165 | 261 | 356 | -2 | 590 |
| Other Working Capital | 368 | 299 | 212 | 76 | 631 |
| Other Operating Activity | -24,328 | -3,045 | -1,373 | -1,322 | 2,306 |
| Operating Cash Flow | $-373 | $-2,152 | $-1,819 | $-1,641 | $343 |
| Cash Flows From Investing Activities | |||||
| Other Investing Activity | -7,000 | -5,000 | -5,000 | 0 | 0 |
| Investing Cash Flow | $-7,000 | $-5,000 | $-5,000 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | -742 | -28,198 | -27,023 | -26,622 | -26,457 |
| Other Financing Activity | -9,430 | 17,490 | 27,012 | 33,650 | 32,736 |
| Financing Cash Flow | $-10,172 | $-10,708 | $-11 | $7,028 | $6,279 |
| Exchange Rate Effect | 0 | -1 | 0 | -1 | 1 |
| Beginning Cash Position | 50,180 | 68,040 | 68,040 | 68,040 | 68,040 |
| End Cash Position | 32,635 | 50,180 | 61,210 | 73,425 | 74,663 |
| Net Cash Flow | $-17,545 | $-17,860 | $-6,830 | $5,385 | $6,623 |
| Free Cash Flow | |||||
| Operating Cash Flow | -373 | -2,152 | -1,819 | -1,641 | 343 |
| Free Cash Flow | -373 | -2,152 | -1,819 | -1,641 | 343 |